-
Within a week, more than 30 new drugs were added in China
Time of Update: 2021-12-25
According to data, the Huzhen Qingfeng Capsules approved for marketing this time are innovative Chinese medicines developed on the basis of clinical experience and the holder is Yili Pharmaceutical Co.
-
Announcement of Proposed Selection Results of Centralized Procurement of Proprietary Chinese Medicine Interprovincial Alliance
Time of Update: 2021-12-25
On the evening of December 21, the Office of the Central Procurement Leading Group of the Inter-Provincial Alliance of Chinese Patent Medicines issued the "Announcement of the Proposed Selection Results of the Inter-Provincial Alliance of Chinese Patent Medicines for Centralized Procurement .
-
Domestic substitution continues to accelerate, how should pharmaceutical machinery companies embrace new opportunities?
Time of Update: 2021-12-25
Pharmaceutical machinery companies are embracing a new round of opportunities (Source: Pharmaceutical Network) For example, Chutian Technology stated in an institutional survey on July 19 that the company had already deployed import substitution in the high-end market of vaccine products three years ago.
-
Shandong pharmaceutical company will win over 4 billion rosuvastatin calcium tablets
Time of Update: 2021-12-25
According to data from Mi Nei. com, the total sales of this product in China's public medical institutions and physical pharmacies in cities in China will exceed 4 billion yuan in 2020 .
-
Kelun enters the market with a $2 billion large variety to grab the second domestic product
Time of Update: 2021-12-25
The first domestic imitation of this product was taken by CSPC in March this year; on December 20, Hunan Kelun Submitted the application for the imitation of Cefmetazole Sodium/Sodium Chloride Injection for 3 types of listing.
-
Difficult to solve medication
Time of Update: 2021-12-25
In the next step, we should continue to strengthen the research and development of rare disease treatment drugs, implement in-depth priority review and approval, and promote the inclusion of medical insurance drugs in the catalog, so as to solve the problem of rare disease patients' medication use, and further give them hope .
-
10 million dollars!
Time of Update: 2021-12-25
However, at present, China's radionuclide therapy still faces some urgent problems that need to be resolved, including the delay in R&D, production, and supply of Chinese pharmaceutical companies, making it difficult to meet clinical needs; the long period of radiopharmaceutical approval; laws, regulations, and regulatory systems are not complete; inspections Or the cost of treatment is expensive, which hinders the healthy development of nuclear medicine in China to a certain extent .
-
If you want high-quality Chinese medicinal materials, you must do a good job
Time of Update: 2021-12-25
The sampling methods and methods submitted for inspection must be reasonable and effective to meet the requirements and standards of quality inspection (batch: the environmental conditions of the planting site are basically the same, the seeds and seedlings and the production cycle are the same, the production The same batch of Chinese medicinal materials with consistent management measures, consistent harvesting and production area processing, and uniform quality) .
-
The clinical results of the A3AR agonist introduced by CMS disclosed the original research company's share price soared 73%
Time of Update: 2021-12-25
Can-Fite is expected to start the recruitment of Namodenoson's key Phase III trial patients in the first quarter of 2022 for the treatment of advanced HCC patients with potential Child Pugh B7 (CPB7) liver cirrhosis to support the submission of new drug applications (NDA) and Approved .
-
Pharmaceutical companies are increasing investment in environmental protection, and are promoting the accelerated development of pharmaceutical machinery companies
Time of Update: 2021-12-25
Among them, it is worth mentioning that in addition to direct construction of environmental protection projects, many pharmaceutical companies have chosen to accelerate the upgrade, replace more energy-saving and efficient, and environmentally friendly pharmaceutical equipment to promote the "green" development of the pharmaceutical sector .
-
As the antibacterial drug market continues to expand, pharmaceutical companies are accelerating the deployment of innovative drugs
Time of Update: 2021-12-25
For example, Zai Lab's two new class 1 drugs, omacycline tosylate tablets and omacycline tosylate for injection, were approved for marketing, becoming the fourth and fifth systemic antibacterial innovative drugs approved this year .
-
Dr. Shen Huaqiong from Tianjing Biotech will leave his post. Exclusive reply: I hope to return to our business——CNS drug development
Time of Update: 2021-12-25
Huaqiong Shen before joining Tianjing Biotechnology, and talked about its career from accidental "medicine" to compound doctor, from clinical drug researcher to pharmacist .
Shen Huaqiong's resignation broke out, Tianjing Bio also reported a number of executive personnel changes:Dr.
-
Clinical trials are increasingly "burning money", how should innovative pharmaceutical companies deal with the challenges?
Time of Update: 2021-12-25
For example, Fuhong Henlius recently revealed on the Global R&D Day that a large internal clinical trial project, compared to handing over to a CRO (contract research organization) enterprise, a self-built clinical trial team can The patient's cost is reduced by nearly half .
-
Guilin Sanjin: The actual controller and chairman Zou Jieming dies
Time of Update: 2021-12-25
Zou Jieming, the actual controller and chairman (and legal representative) of the company, died of illness on December 21, 2021, at the age of 80 .
-
The National Medical Insurance Administration officially launched the three-year action plan for the reform of DRG/DIP payment methods
Time of Update: 2021-12-25
The first China CHS-DRG/DIP payment method reform conference was held in Beijing a few days ago. The National Medical Insurance Administration announced the official launch of the three-year action
-
Move the pharmaceutical factory into space?
Time of Update: 2021-12-25
According to the industry, the completion of China's space station will provide a new innovative carrier for the development of Chinese medicine, help the overall innovation and promotion of Chinese medicine, and bring space technology to benefit human life and health .
-
Biopharmaceutical front-end equipment is accelerating iterative upgrades, and domestic substitution will accelerate in the future
Time of Update: 2021-12-25
In the middle and late stages, companies also need to pay attention to the cultivation of craftsmanship, continue to improve manufacturing levels, and improve product quality in order to share more shares in the high-end pharmaceutical equipment market and further accelerate the pace of domestic substitution .
-
Jingdong has opened pharmacies nationwide!
Time of Update: 2021-12-25
In the first half of this year, JD Health and JD Logistics established a drug "self-operated cold chain" capability covering 100 cities in 12 provincial administrative regions across the country.
-
Over 1 billion U.S. dollars!
Time of Update: 2021-12-25
The company is using its proprietary XPAT and XPAC platforms to develop a series of new drugs that can be preferentially activated in the tumor microenvironment to overcome the side effects of T cell therapy and cytokine therapy .
-
The harvest time for new Chinese medicines has come, and the number of approved drugs hits a record high
Time of Update: 2021-12-25
In short, innovative research and development of traditional Chinese medicine is rapidly emerging .
